328 related articles for article (PubMed ID: 26968417)
1. Neoadjuvant Treatment of High-Risk, Clinically Localized Prostate Cancer Prior to Radical Prostatectomy.
Pietzak EJ; Eastham JA
Curr Urol Rep; 2016 May; 17(5):37. PubMed ID: 26968417
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness comparison between neoadjuvant chemohormonal therapy and extended pelvic lymph node dissection in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis.
Matsumoto T; Hatakeyama S; Ookubo T; Mitsuzuka K; Narita S; Inoue T; Yamashita S; Narita T; Koie T; Kawamura S; Tochigi T; Tsuchiya N; Habuchi T; Arai Y; Ohyama C
Med Oncol; 2017 Oct; 34(12):190. PubMed ID: 29090390
[TBL] [Abstract][Full Text] [Related]
3. Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial.
Sumiyoshi T; Wang X; Warner EW; Sboner A; Annala M; Sigouros M; Beja K; Mizuno K; Ku S; Fazli L; Eastham J; Taplin ME; Simko J; Halabi S; Morris MJ; Gleave ME; Wyatt AW; Beltran H
J Natl Cancer Inst; 2024 Jan; 116(1):115-126. PubMed ID: 37676819
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Strategies Before Radical Prostatectomy for High Risk Prostate Cancer in the Era of New Hormonal Agents.
Tafuri A; Cerruto MA; Antonelli A
Curr Drug Targets; 2021; 22(1):68-76. PubMed ID: 32564752
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer.
Sella A; Zisman A; Kovel S; Yarom N; Leibovici D; Lindner A
Urology; 2008 Feb; 71(2):323-7. PubMed ID: 18308112
[TBL] [Abstract][Full Text] [Related]
6. Overall survival of high-risk prostate cancer patients who received neoadjuvant chemohormonal therapy followed by radical prostatectomy at a single institution.
Fujita N; Koie T; Ohyama C; Tanaka Y; Soma O; Matsumoto T; Yamamoto H; Imai A; Tobisawa Y; Yoneyama T; Hatakeyama S; Hashimoto Y
Int J Clin Oncol; 2017 Dec; 22(6):1087-1093. PubMed ID: 28681153
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer.
Cha EK; Eastham JA
Urol Oncol; 2015 May; 33(5):217-25. PubMed ID: 25596644
[TBL] [Abstract][Full Text] [Related]
8. Early use of chemotherapy in conjunction with radical prostatectomy.
Alumkal JJ; Carducci MA
Clin Prostate Cancer; 2004 Dec; 3(3):144-9. PubMed ID: 15636680
[TBL] [Abstract][Full Text] [Related]
9. CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-naïve oligometastatic prostate cancer.
Sheikhbahaei S; Reyes DK; Rowe SP; Pienta KJ
Prostate; 2021 Feb; 81(2):127-134. PubMed ID: 33259087
[TBL] [Abstract][Full Text] [Related]
10. Systemic treatments for high-risk localized prostate cancer.
Pignot G; Maillet D; Gross E; Barthelemy P; Beauval JB; Constans-Schlurmann F; Loriot Y; Ploussard G; Sargos P; Timsit MO; Vincendeau S; Pasticier G; Borchiellini D
Nat Rev Urol; 2018 Aug; 15(8):498-510. PubMed ID: 29765147
[TBL] [Abstract][Full Text] [Related]
11. A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients.
Womble PR; VanVeldhuizen PJ; Nisbet AA; Reed GA; Thrasher JB; Holzbeierlein JM
J Urol; 2011 Sep; 186(3):882-7. PubMed ID: 21791342
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival of patients with locally advanced prostate cancer managed with neoadjuvant docetaxel and radical prostatectomy.
Zhao B; Yerram NK; Gao T; Dreicer R; Klein EA
Urol Oncol; 2015 Apr; 33(4):164.e19-23. PubMed ID: 25665510
[TBL] [Abstract][Full Text] [Related]
13. [Significance of neoadjuvant therapy before radical prostatectomy].
Paul R; Van Randenborgh H; Kübler H; Alschibaja M; Hartung R
Urologe A; 2004 Jun; 43(6):680-8. PubMed ID: 15148572
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.
Prayer-Galetti T; Sacco E; Pagano F; Gardiman M; Cisternino A; Betto G; Sperandio P
BJU Int; 2007 Aug; 100(2):274-80. PubMed ID: 17355369
[TBL] [Abstract][Full Text] [Related]
15. Baseline Testosterone Levels in Men with Clinically Localized High-Risk Prostate Cancer Treated with Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy (Alliance).
Eastham JA; Heller G; Hillman DW; Hahn OM; Parsons JK; Mohler JL; Small EJ; Morris M
J Urol; 2021 Aug; 206(2):319-324. PubMed ID: 33780276
[TBL] [Abstract][Full Text] [Related]
16. Multimodal treatment strategies combining neoadjuvant hormonal therapy and/or chemotherapy with radical prostatectomy in high-risk localised prostate cancer.
Eastham JA
Expert Opin Investig Drugs; 2004 Jan; 13(1):39-46. PubMed ID: 14680451
[TBL] [Abstract][Full Text] [Related]
17. High-risk localised prostate cancer: multimodal treatment strategies combining neoadjuvant hormonal therapy and/or chemotherapy with radical prostatectomy.
Eastham JA
Expert Opin Emerg Drugs; 2003 Nov; 8(2):291-5. PubMed ID: 14661990
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer.
Vuky J; Porter C; Isacson C; Vaughan M; Kozlowski P; Picozzi V; Corman J
Cancer; 2009 Feb; 115(4):784-91. PubMed ID: 19130458
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial.
Kim WY; Whang YE; Pruthi RS; Baggstrom MQ; Rathmell WK; Rosenman JG; Wallen EM; Goyal LK; Grigson G; Watkins C; Godley PA
Urol Oncol; 2011; 29(6):608-13. PubMed ID: 20022268
[TBL] [Abstract][Full Text] [Related]
20. [Radical prostatectomy with neoadjuvant hormone therapy for cT3 prostate cancer].
Fujimoto H
Nihon Rinsho; 2005 Feb; 63(2):271-8. PubMed ID: 15714978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
